The project aims to enable flexibility and integration to ensure consistent graphics experiences across diverse platforms ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

The two companies are integrating Producer’s project workflow tools with Cree8’s collaboration, storage and workstation tools ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...